In multiple myeloma (MM), inhibition of TRPV1, which is involved in the regulation of calcium signalling, induces the accumulation of mitochondrial calcium and decreases the level of HSP70 induced by bortezomib, thereby impairing protein folding capacity and sensitizing MM cells to bortezomib [69]. Here, TRPV1 is linked to Miyoshi myopathy.